CSL Vifor and Travere Therapeutics (TVTX) announced that the European Commission has approved the conversion of the conditional marketing approval into a standard marketing authorization for Filspari for the treatment of adults with primary IgA nephropathy with a urine protein excretion of 1.0 g/day. Standard MA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- TVTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tax Day 2025 IRS Payment: Stocks to Consider Buying With the Refund
- Travere Therapeutics price target lowered to $30 from $32 at Scotiabank
- Travere Therapeutics price target raised to $47 from $45 at Canaccord
- Travere Therapeutics price target lowered to $27 from $31 at BofA